{
  "docId": "019de070-6ba7-74d1-848b-b84c997820ae",
  "docSlug": "fd4b4c87c265fc439333e9f58c5ae8a7",
  "documentTitle": "Compass Therapeutics | IPO Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 40,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-6ba7-74d1-848b-b84c997820ae/6",
  "deckHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae",
  "deckJsonHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae.json",
  "deckAnchorHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.06,
        "y": 0.00185
      },
      "kind": "list",
      "text": "In June Compass completed a $60 million financing combined with a reverse merger with a Form 10 public shell\nExpanded Compass investor base\nCTX-471 Phase 1 Clinical Trial\nPhase 1a Dose Escalation completed\nPhase 1b Dose Expansion Study has begun: first patient treated\nCTX-8371 advanced to IND-enabling studies\nGMP manufacturing initiated in August\nPlanning for additional fundraising\nCTX-471 combination study with trastuzumab and/or cetuximab\nAdvance our first NKp30 innate cell engager",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d1d2710-bf6f-4812-a8f6-f09899dbf78e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.27,
        "x": 0.025,
        "y": 0.085
      },
      "kind": "title",
      "text": "Recent Events",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f56aed4a-059f-4aeb-907b-9cadb95fe8ea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8f23aa4f-73de-402c-b124-1353a7937adb",
      "evidence": "The deck presents a clear 'why' throughout, with a focus on the team's expertise and the pipeline's potential",
      "position": 1,
      "objective": "Why Compass Therapeutics, and why now?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}